LIXTE Biotechnology Holdings announced the appointment of Lourdes Felix and Guy Primus to its Board of Directors and Peter Stazzone as Chief Financial Officer.
The company also relocated its corporate headquarters to Boca Raton, Florida.
Bas van der Baan remains Chief Scientific Officer, and René Bernards, PhD, is the new Chairman of the Scientific Advisory Board.
New Leadership
LIXTE welcomes experienced professionals to strengthen its leadership team.
Strategic Moves
Relocation to Florida aims to enhance operational efficiency and long-term value for shareholders.
Financial Expertise
Peter Stazzone brings over 20 years of financial management experience to the role of CFO.
- The addition of new board members and a CFO signals LIXTE's commitment to growth and development.
- Relocating to a business-friendly environment in Florida may lead to cost reductions and strategic advantages.
- Continued focus on developing proprietary compounds and advancing cancer therapies is central to LIXTE's mission.
The strategic appointments and headquarters relocation mark an exciting phase for LIXTE as it aims to drive innovation in cancer therapy and create value for stakeholders.